Literature DB >> 11291530

Influence of novel and conventional antipsychotic medication on subjective quality of life.

R Tempier1, N Pawliuk.   

Abstract

OBJECTIVE: To assess the impact of novel antipsychotic medication on the subjective quality of life of patients with schizophrenia and schizoaffective disorders.
DESIGN: Retrospective, cross-sectional analysis of data from 2 studies conducted in 1997 and 1998. PATIENTS: 91 outpatients (50 men and 41 women, mean age 43.3 years) diagnosed with schizophrenia (n = 70) and schizoaffective disorder (n = 21); the mean Global Assessment of Functioning score for these patients was 48.0 (standard deviation 12.5). OUTCOME MEASURE: Patients were categorized into 1 of 3 groups: those taking conventional (n = 41), novel (n = 26) or mixed (both conventional and novel) (n = 24) antipsychotics. Responses on the Satisfaction with Life Domains Scale were used to assess subjective quality of life.
RESULTS: The type of antipsychotic medication taken did not influence satisfaction with life scores; in fact, 2 items dealing with social relationships were scored lower by those taking novel antipsychotics.
CONCLUSIONS: Patients taking novel antipsychotics may expect more from life, and this might explain their lower quality-of-life scores.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11291530      PMCID: PMC1407744     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  20 in total

Review 1.  Quality of life of schizophrenic patients on medications and implications for new drug trials.

Authors:  A G Awad
Journal:  Hosp Community Psychiatry       Date:  1992-03

2.  Quality of life in the evaluation of community support systems.

Authors:  F Baker; J Intagliata
Journal:  Eval Program Plann       Date:  1982

3.  Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.

Authors:  H Y Meltzer; S Burnett; B Bastani; L F Ramirez
Journal:  Hosp Community Psychiatry       Date:  1990-08

4.  Quality of life rediscovered: implications for clinical outcome and health economics in schizophrenia.

Authors:  A G Awad
Journal:  J Psychiatry Neurosci       Date:  1997-07       Impact factor: 6.186

5.  A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.

Authors:  B C Ho; D Miller; P Nopoulos; N C Andreasen
Journal:  J Clin Psychiatry       Date:  1999-10       Impact factor: 4.384

6.  A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation.

Authors:  A G Awad; L N Voruganti; R J Heslegrave
Journal:  Qual Life Res       Date:  1997-01       Impact factor: 4.147

7.  Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

Authors:  D A Revicki; L A Genduso; S H Hamilton; D Ganoczy; C M Beasley
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

Review 8.  Measuring quality of life in patients with schizophrenia.

Authors:  A G Awad; L N Voruganti; R J Heslegrave
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

9.  The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.

Authors:  D W Heinrichs; T E Hanlon; W T Carpenter
Journal:  Schizophr Bull       Date:  1984       Impact factor: 9.306

10.  [Who are the patients treated in an outpatient clinic with high dosage neuroleptics?].

Authors:  G Leblanc; H J Cormier; S Vaillancourt; M A Gagné; C Gingras
Journal:  Can J Psychiatry       Date:  1990-02       Impact factor: 4.356

View more
  5 in total

Review 1.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

Review 2.  Impact of atypical antipsychotics on quality of life in patients with schizophrenia.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  Patients' subjective experiences of antipsychotics: clinical relevance.

Authors:  Jonathan S E Hellewell
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Combination therapy or monotherapy for the depressed type of schizoaffective disorder.

Authors:  Lubomira Izáková; Ivan Andre; Angelos Halaris
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

5.  Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-20).

Authors:  Melina Siamouli; Katerina Moutou; Eleonora Pantoula; Stamatia Magiria; Irini Chatzivasileiou; Konstantinos Arapidis; Achileas Chatzivasileiou; Simeon Deres; Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2009-01-21       Impact factor: 3.455

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.